News Release

COVID-19 severity and waning immunity after up to 4 mRNA vaccine doses in patients with cancer

JAMA Oncology

Peer-Reviewed Publication

JAMA Network

About The Study: This study provides evidence of the clinical effectiveness of mRNA-based vaccines against COVID-19 in patients with cancer. Longevity of immunity in preventing severe COVID-19 outcomes in actively treated patients with cancer, cancer survivors, and matched controls was observed at least five months after the third or fourth dose. 

Authors: Raghav Sundar, M.B.B.S., Ph.D., of the National University Health System in Singapore, and Kelvin Bryan Tan, Ph.D., of the Ministry of Health in Singapore, are the corresponding authors. 

To access the embargoed study: Visit our For The Media website at this link 


Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.